Ignacio Pino, DVM
Chief Executive Officer; Co-Founder
Ignacio is a co-founder, President, and CEO of CDI Labs and has been developing and commercializing monoclonal antibodies and proteomic tools since co-founding the company. He built successful academic and industrial partnerships across the US, and in Europe, China, South Korea and the Caribbean, and established the MonomabsTM monoclonal antibody development pipeline at CDI Labs.
Ignacio successfully raised angel and private investments, and secured over $11.5 million in local and NIH grants for CDI Labs. This included funding to develop highly-specific monoclonal antibodies in collaboration with Johns Hopkins University, and funding to produce commercial HIV vaccines in collaboration with the University of Puerto Rico, Mayaguez. He is developing protein microarray-based immunoassays for infectious diseases, and is commercializing a protein microarray to profile functional membrane proteins, which could potentially transform how ligands and drugs that bind human membrane proteins are screened.
A graduate of the University of Puerto Rico, Mayaguez, Ignacio earned a DVM from the Ross University School of Veterinary Medicine in St. Kitts, followed by clinical training at Kansas State University. Prior to founding CDI Labs, he ran a veterinary consultation business, and conducted tick-borne disease and vaccine research at University Products, LLC. Ignacio was a Guayacán Tech Fellow at the MIT Entrepreneurship Development Program, and represented CDI Labs at the first White House Demo Day, hosted by President Barack Obama.
Vice President of Sales and Business Development
Scott Paschke is CDI Labs’ Vice President of Sales and Business Development. With over 20 years of experience in the biotechnology sector working with renowned R&D reagent companies, Scott leads our business and commercial strategy to help clients accelerate their research and discoveries with CDI Labs’ innovative tools.
“We are working at a very exciting time! Science and cancer treatments are moving at a furious pace. I love meeting with some of the best minds in the field and working with our customers to accelerate the development of new treatments and diagnostics.”
Scott received a BA in biology and a MA in biochemistry from State University College at Buffalo. Prior to joining CDI Labs, Scott was Director of Business Development at Active Motif, and was President and Chief Technology Officer at Lake Placid Biologics. He also held leadership positions at Serologicals Corporation, Lake Placid Biologicals and Upstate Inc. Scott’s background in fundraising, biotechnology licensing and tech transfer was instrumental in shaping CDI Labs’ business plan for an initial round of fund-raising. In addition to directing sales and marketing and business development, he also works closely with staff scientists on operational issues. Scott has played a key role in creating partnerships between academic researchers and CDI Labs, helping them commercialize innovative products.
Daniel Eichinger, PhD
Chief Scientific Officer; Co-Founder
Dan is CDI Labs’ Chief Scientific Officer and a co-founder. He received his PhD from the NYU School of Medicine, and did post-doctoral research at the Johns Hopkins University School of Medicine. Prior to joining CDI Labs, he was chair of the Department of Parasitology at NYU Medical School. With almost 30 years of experience at the NYU School of Medicine and Johns Hopkins University School of Medicine, Dan’s academic interests spanned molecular biology, genetics, and immunology of bacteria, yeast and medically-relevant parasitic diseases such as malaria, amebiasis and trypanosomiasis.
“Most satisfying to me about CDI Labs is being able to help combine long-established and cutting-edge proteomics technologies to generate protein products of a quality that was not previously possible, and making those products available to the basic and applied research community I was once part of. In a few short years, those products have led to a large, and growing, number of scientific and medical discoveries.”
At CDI Labs, Dan develops microarray and ELISA-based platforms that take advantage of both the highly-specific monoclonal antibodies and a high-content human protein arrays that are manufactured at CDI Labs. An expert in monoclonal antibody development and in recombinant protein development and production, Dan played a critical role in building CDI Labs’ FAST-MabTM platform. His work at CDI has contributed to disease biomarker discoveries in lung cancer, creation of multiplex biomarker panels for distinguishing Dengue and Zika viral infections, as well as creation of the VirDTM array and characterization of monoclonal antibody binding kinetics.
Shaohui Hu, PhD
Director, Proteomic Sciences
With over 15 years of experience in high-throughput studies of networks and pathways using protein microarray technology, Dr. Hu supervises the proteomic research activities and client projects at CDI, including high-throughput subcloning and protein purification, protein microarray production and applications in biomarker discovery, protein-protein, -RNA, -DNA interactions, antibody specificity characterization and substrate identification, etc. Dr. Hu is also in charge of the optimization and troubleshooting of array products and services, as well as development of new technologies and products.
Tyler Hulett, PhD
Director, Immuno-Oncology & Biomarker Development
Dr. Hulett has a decade of scientific expertise, including doctoral and post-doctoral work focused on the use of antibody biomarkers in one of the world’s top translational cancer immunotherapy groups. Dr. Hulett is building integrative data pipelines to create broader uses for existing CDI platforms and will help direct future product design and development. CDI clients benefit from his clinical and preclinical experience with protein arrays, multispectral immunohistochemistry, lymphocyte biology, and cancer vaccines.
“It’s an honor to get to work at CDI alongside some of the world’s best synthetic biologists. I think these proteomics tools my colleagues built will help unravel the great mysteries of inflammatory disease – and lead to discoveries of new antigen-specific mechanisms underlying everything from dementia to cancer. “
Board of Directors
Jef Boeke, PhD
Co-Founder; Board Member
Jef is a co-founder of CDI Labs, and the Founding Director of the Institute for Systems Genetics at NYU Langone Medical Center. His foundational work on retrotransposition led to technological innovations in genetics, genomics and synthetic biology, used to study how retrotransposition affects human reproductive cells, non-reproductive cells, and cancer. Jef also leads the Synthetic Yeast Genome Project, an international and collaborative effort aiming to design and build the 16 synthetic chromosomes of the world’s first designer eukaryotic cell.
A graduate of Bowdoin College, Jef received a PhD in Molecular Biology from the Rockefeller University, followed by postdoctoral work at MIT/Whitehead Institute. He was on the faculty of the Department of Molecular Biology & Genetics at the Johns Hopkins University School of Medicine from 1986-2014, where he also founded the High Throughput Biology Center. He is a co-founder of the biotechnology companies Avigen and CDI Labs, and was elected to the National Academy of Sciences in 2013.
Joe Bonaventura, PhD
Co-Founder; Board Member
Joe is a co-founder of CDI Labs, and Professor Emeritus of Marine Science and Conservation at the Nicholas School of the Environment at Duke University. His expertise lies in biochemical studies on the structural and functional diversity of marine organisms from diverse environments, and he did his research at Duke University Medical Center and Duke Marine Lab, where also he founded and directed the Duke Marine Biomedical Center. An author on over 200 publications, Joe also received 40 patents for his inventions. In addition to numerous academic and editorial affiliations, Joe was a board member of the North Carolina Biotechnology Center, the first state-sponsored biotechnology initiative in the United States, and also served on the Science Advisory Board of National Public Radio.
Joe received degrees in chemistry and biology from San Diego State College, and a PhD in Biochemistry from the University of Texas at Austin. He did postdoctoral research at the California Institute of Technology and at Regina Elena Cancer Institute in Rome, Italy. He has been instrumental in establishing research and development collaborations at CDI Labs, building a broad and collaborative network of scientists from top research institutions around the world.
Antoine de Marsily, MBA
Antoine de Marsily is the Managing Director at Independent Capital LL, in San Juan, Puerto Rico. He represented Apollo Ventures, the lead investor of CDI’s Series A round. He has also served as the Executive Vice President at Grupo VL, LLC since 2011. Formerly, he was Executive Vice President at Alara Pharmaceutical Corp, and VP of Operations at Mova Pharmaceutical Corp. Antonine received a degree in aerospace, aeronautical and astronautical engineering from WSU. He also received an MBA and a Masters in International Economics and Management from SDA Bocconi in Italy. A native of France, Antoine is the Honorary Consul for France in Puerto Rico.
Paul Horan, PhD
Paul is president and CEO of Targeted Cancer Therapeutics and president of Prescriptive Kinetics. He was previously affiliated with GTC Biotherapeutics, QED Technologies, Zynaxis Cell Science, and Smith, Kline & French. Paul brings a unique balance of creative, strategic, business, technical and scientific capabilities from over 20 years of experience. As a hands-on founder of three companies, Paul is committed to building both businesses and employees’ careers. He has R&D experience in diverse pharmaceutical, biopharmaceutical and drug delivery areas, and over 10 years of executive experience. His international work with both big pharma and small companies has allowed him to appreciate different perspectives and negotiate mutually beneficial deals. He enjoys wide networking relationships with corporate executives, scientists, legal professionals and investors throughout the biotech and pharma sectors, and is a nationally recognized speaker on valuations and deal negotiation.
Paul earned degrees in Math, Physics and Education from the State University of New York at Albany. He earned an MS and PhD in radiation biophysics from Pennsylvania State University, followed by postdoctoral studies at Sloan Kettering Institute for Cancer Research. He has over 60 scientific publications and is author on six patents.
Scientific Advisory Board
Heng Zhu, PhD
Co-Founder; SAB Member
Heng is a co-founding member of the CDI Labs. He is a professor in the Department of Pharmacology at Johns Hopkins Medical School. A graduate of Beijing University, he earned his PhD at Clemson University with Ralph Dean, followed by postdoctoral work at Yale with Mike Snyder, where he created the first proteome microarray for a eukaryote. This work was eventually licensed by Invitrogen to create their ProtoArray. Heng’s large-scale studies of protein networks using protein arrays have led to many unique technological innovations, including both the high-density Human Proteome Microarray (HuProtTM) and VirDTM array technologies now produced at CDI Labs.
In addition to his studies on the functions of large networks of proteins, Heng has used proteomics to understand how microbes and viruses sustain themselves within human hosts. In the area of human disease biomarker discovery, Heng works closely with international collaborators and has published studies on human autoimmune diseases (Inflammatory Bowel Disease), infectious disease (including SARS, herpes, Zika, and dengue), chronic conditions (Parkinson’s and Alzheimer’s diseases) and human cancers (including lung, ovarian, stomach and glioma).
Seth Blackshaw, PhD
Co-Founder; SAB Member
Seth Blackshaw is a professor of neuroscience, neurology and ophthalmology at the Johns Hopkins School of Medicine, and a member of the Institute for Cell Engineering. A co-founding member of CDI Labs, he collaborated with Professor Heng Zhu to create HuProtTM, the human proteome microarray.
“I helped co-create HuProtTM because I was interested in getting the best quality tools, including monoclonal antibodies, into the hands of the biomedical research community.”
Prof. Blackshaw received degrees in biochemistry from the University of Chicago and a PhD in Neuroscience from Johns Hopkins School of Medicine, and performed postdoctoral research at Harvard Medical School. His research has focused on the regulation of cell fate specification and neuronal regeneration in retina and hypothalamus, hypothalamic regulation of innate behaviors such as sleep and feeding, and the development of new tools for functional proteomics. He also led a collaborative CDI Labs – Johns Hopkins effort under a five-year NIH-funded effort to generate ultraspecific, protein microarray-validated, monoclonal antibodies.
He has received numerous awards, including the Sloan Foundation Research Fellowship, the Esther A. and Joseph Klingenstein Fellowship in the Neurosciences, and the W. M. Keck Foundation Distinguished Young Scholar in Medical Research Award.
Prashant Desai, PhD
Prashant is an associate professor at the Department of Oncology at the Johns Hopkins School of Medicine, and is based at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. He studies Herpes Simplex 1 virus (HSV-1), with an eye towards elucidating virus-encoded functions in the infectious pathway that are suitable for anti-viral drug treatment.
In collaboration with CDI Labs and Professor Heng Zhu at Johns Hopkins, Prashant has also developed an innovative, high-content Virion Display (VirDTM) array to display G-protein-coupled receptors (GPCRs) on the lipid envelope of the herpesvirus virion. This diverse group of cell surface receptor proteins act as an inbox for messages in the form of light, energy, peptides, lipids, sugars, and proteins. While they have long been viewed with great interest as potential targets for drug treatment, they have been difficult to study as they require membranes to fold and function properly. The VirD-GPCR array is the first-complete tool for screening small molecule drugs and protein affinity reagents in high-throughput. Prashant hopes this will lead to the discovery of useful new ligands, and eventually therapeutics that can bind to these elusive receptor proteins.
Jiang Qian, MS, PhD
Jiang is the Karl H. Hagen Professor in Opthalmology at the Wilmer Eye Institute, and director of the Wilmer Bioinformatics Group and Bioinformatics core facility at Johns Hopkins University. His work focuses on computational modeling of retinal development and disease. He also holds a joint appointment at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. A pioneer in ocular informatics, Jiang has made substantial and innovative contributions to his field. Specifically, his group develops and applies bioinformatics approaches to study gene regulation and signaling networks, with particular attention to the mammalian retina. Understanding the molecular basis of tissue-specific gene regulation and signaling will contribute to better prevention, diagnosis and treatment of retinal diseases, such as macular degeneration.
Jiang received an M.S. in computational biology from Shanghai Biochemistry Institute in Shanghai, China, and his PhD in physical chemistry from Max Planck Institute for Polymer Research in Mainz, Germany. He then completed postdoctoral training on bioinformatics at Yale University. He has published more than 120 papers in prestigious and specialized journals, including Cell, Nature Reviews Genetics and Molecular Systems Biology. His research is supported primarily by federal funding agencies, including the National Institutes of Health, as well as private funding agencies.
Kim Blenman, MS, PhD
Kim is an Associate Research Scientist at the Yale University Department of Internal Medicine, Section of Medical Oncology and Yale Cancer Center. She develops research tools and software to understand how patients differ in disease progression and in their response to treatment. She received a B.S. in chemistry and M.S. in clinical chemistry, followed by a doctorate in immunology from the University of Florida.
Kim previously worked in drug discovery and clinical development at Proctor and Gamble. She has published methods, software tool workflow, and data standards for flow cytometry and high complexity histology in the study of disease, and her research interests include breast neoplasms, leukemia, lymphoma, melanoma and multiple myeloma. She is presently working on several breast cancer clinical studies, using cytometry and high complexity histology to analyze the tumor microenvironments in patients who have been received immunotherapy to activate or suppress their immune systems. She is particularly interested in the results of the treatments on patients from different racial and ethnic groups, and the implications of these findings on treatment outcomes and health equality.
Kim helped to develop the Vectra Quantitative Multispectral Imaging System for immunology applications, commercialized by Perkin-Elmer, an all-in-one tool for automated imaging and analysis. She has served on the International Society for the Advancement of Cytometry (ISAC) Data Standards Task Force since 2009. She is a member of the International Immuno-Oncology Biomarker Working Group on Breast Cancer, and has served on several committees for the Society for Immunotherapy of Cancer (SITC). She has received numerous awards, including a Melanoma Research Alliance Young Investigator Award.
Atul Tandon, PhD
Ben Larman, PhD
Ben is an assistant professor in Pathology at Johns Hopkins University, where he also directs The Laboratory of Precision Immunology within the Immunology Division. Ben earned his B.S. in Engineering Physics and Bioengineering from UC Berkeley in California. He obtained a Ph.D. from Harvard-MIT’s Division of Health Sciences & Technology, followed by a postdoctoral fellowship at The Scripps Research Institute.
Ben’s lab develops and deploys cutting-edge technologies to identify new opportunities for monitoring and manipulating human immune responses in sickness and in health. Much of his work leverages ‘next generation’ DNA sequencing, which enables novel, massively parallel molecular measurements to be made with a variety of technologies. Examples of technologies Ben has developed include: phage display of synthetic peptidome libraries to profile large groups of antibodies (PhIP-Seq); ribosome display of ORFeome libraries for antigen discovery, protein-protein interaction studies, and drug target identification; ultrasensitive, multiplex RNA quantification techniques to monitor gene expression and detect microbes; and pooled genetic screening to elucidate immune cell function and identify new therapeutic targets. Ben also makes minimizing the cost of analyzing very large numbers of individual human samples when studying disease associations a high priority.
CDI – Mayagüez
CDI would be nothing without its people. Many biotech companies have operations in Puerto Rico – but we are the first to found one on the island. CEO Ignacio Pino is a native of Mayagüez: the vibrant college town where we base our operations. Over the last decade he’s recruited the best and brightest students from the local UPR-Mayagüez, building a team that has assembled the world’s largest human recombinant protein library and the first catalogue of proteome-validated monoclonal antibodies.
CDI – Baltimore
CDI has deep roots in Baltimore, co-founders Jef Boeke, Heng Zhu, & Seth Blackshaw started the company while they worked as professors at Johns Hopkins University. The company has retained a facility on-campus in the Rangos Life Sciences Building, allowing us close access to our growing Scientific Advisory Board. All HuProt arrays are currently printed by scientists at our Baltimore facility.